Compare BioNTech SE - ADR (BNTX) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Southern Copper Corp — how do they compare? BioNTech SE - ADR trades at $92.99 (market cap $23.31B), while Southern Copper Corp trades at $195 (market cap $164.21B). The key difference: Southern Copper Corp is far larger — about 7× BioNTech SE - ADR's market cap, and Southern Copper Corp pays a 2.26% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | SCCO | |
|---|---|---|
Market Cap | $23.31B | $164.21B |
Sector | Health | Basic Materials |
52-Week High | $119.34 | $218.85 |
52-Week Low | $83.89 | $93.70 |
Enterprise Value | $6.60B | $165.50B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
SCCO trades at $200.11, up 0.53% today, near its pivot point of $201. The stock exhibits strong profitability with a 35.87% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights its rally fueled by strong H1 results and higher copper prices, though production declines and premium valuations are noted concerns (Zacks Investment Research, 2026-08-11).
Outlook is mixed; robust earnings growth and AI-driven copper demand present upside, but high valuation ratios and analyst skepticism pose risks. The consensus price target of $153.64 suggests significant downside from current levels, indicating caution is warranted despite positive technical and fundamental trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
